---
title: Tenofovir slows Parkinson disease progression
nct_id: NCT06356662
phase: PHASE1
status: RECRUITING
sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06356662"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06356662"
last_fetched: "2026-05-10T14:08:41.345Z"
source: "Parkinson's Pathways (curated)"
---
# Tenofovir slows Parkinson disease progression

**Goal (in five words):** Tenofovir slows Parkinson disease progression

**Official Title:** Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

**Trial ID:** [NCT06356662](https://clinicaltrials.gov/study/NCT06356662)

## Key Facts

- **Phase:** PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Target Enrollment:** 60 participants
- **Start Date:** 2024-01-23
- **Completion Date:** 2025-12-31
- **Conditions:** Parkinson Disease
- **Interventions:** Tenofovir Disoproxil Fumarate
- **Intervention Types:** DRUG

## Summary For Families

Researchers are testing whether the antiviral tenofovir disoproxil fumarate can slow or modify Parkinson's by reducing brain inflammation or other processes that may contribute to dopamine neuron damage. In this Phase 1 trial tenofovir, a nucleotide reverse transcriptase inhibitor that blocks viral replication and may lower systemic inflammation, is being repurposed as an oral treatment and will be closely monitored for safety, especially kidney and liver function. No direct interaction with levodopa is expected, but the study will watch for any medication interactions or side effects. The trial enrolls adults 18 to 65 with early-to-mid Parkinson's (Hoehn and Yahr 1 to 2.5) and normal cognition (MMSE ≥24), excluding people with chronic hepatitis B or HIV, abnormal liver or kidney tests, prior brain surgery like DBS, major psychiatric or other serious medical conditions, pregnancy, or allergy to the drug.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24

Exclusion Criteria:

* 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders

  2: Or have received deep brain stimulation and other brain surgery

  3: Abnormal liver and kidney function

  4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)

  5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence

  6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor

  7: Pregnant or lactating women and seniors over 65 years of age

  8: Allergy or other contraindications to the investigational drug
```

## Locations (1)

- Guohua Zhao, Hangzhou, Zhejiang, China _(30.2936, 120.1614)_
  - Zhao Guohua, Doctor — (CONTACT) — +86 13777812308 — gzhao@zju.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT06356662*  
*HTML version: https://parkinsonspathways.com/trial/NCT06356662*  
*Source data: https://clinicaltrials.gov/study/NCT06356662*